Average Insider

Where insiders trade, we follow

$ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Healthcare
Sector
Biotechnology
Industry
Cary John Claiborne
CEO
5
Employees
$2.79
Current Price
$2.94M
Market Cap
52W Low$1.31
Current$2.798.4% above low, 91.6% below high
52W High$19.00

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys14$41,328.6214,986All Buys
Sells00--
2 monthsBuys15$106,328.6239,986All Buys
Sells00--
3 monthsBuys15$106,328.6239,986All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 16, 2026
Coastlands Capital LP
10% Owner
Purchase1,233$2.75$3,390.75View Details
Jul 14, 2026
Coastlands Capital LP
10% Owner
Purchase2,000$2.65$5,300.00View Details
Jul 9, 2026
Coastlands Capital LP
10% Owner
Purchase10,053$2.79$28,047.87View Details
Jul 10, 2026
Coastlands Capital LP
10% Owner
Purchase1,700$2.70$4,590.00View Details
Jun 29, 2026
Coastlands Capital LP
10% Owner
Purchase25,000$2.60$65,000.00View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.7.3